Abstract
The Ras-MAPK pathway is important to orchestrating a cells response to external and internal stimuli. This pathway is commonly dysregulated in cancer, including bladder cancer. Multiple components of this complex pathway have been identified as potential targets for drug development. After initial preclinical studies many drugs targeting the Ras-MAPK pathway are being studied in phase II clinical trials for advanced bladder cancer either alone or in combination with other chemotherapeutic agents. Drugs presently in clinical trials inhibit the tyrosine kinases, including FGFR, EGFR, ERBB2, and PDGF, either through small molecule tyrosine kinase, dual kinase or farnesyltransferase inhibitors. Recent drug patents targeting the Ras-MAPK pathway in cancer are becoming more selective with the potential for improved therapeutic response and better toxicity as compared to the more universal MAPK pathway inhibitors. In the present review we summarize the importance of the Ras-MAPK pathway in cancer with a focus on bladder cancer and discuss current drugs and recent patents (2004-2008) that target this important pathway in bladder cancer.
Keywords: Bladder cancer, Ras-MAPK pathway, new potential therapeutic targets
Recent Patents on Anti-Cancer Drug Discovery
Title: Ras-MAPK Pathway as a Therapeutic Target in Cancer - Emphasis on Bladder Cancer
Volume: 4 Issue: 2
Author(s): Pankaj P. Dangle, Boriana Zaharieva, Hongtao Jia and Kamal S. Pohar
Affiliation:
Keywords: Bladder cancer, Ras-MAPK pathway, new potential therapeutic targets
Abstract: The Ras-MAPK pathway is important to orchestrating a cells response to external and internal stimuli. This pathway is commonly dysregulated in cancer, including bladder cancer. Multiple components of this complex pathway have been identified as potential targets for drug development. After initial preclinical studies many drugs targeting the Ras-MAPK pathway are being studied in phase II clinical trials for advanced bladder cancer either alone or in combination with other chemotherapeutic agents. Drugs presently in clinical trials inhibit the tyrosine kinases, including FGFR, EGFR, ERBB2, and PDGF, either through small molecule tyrosine kinase, dual kinase or farnesyltransferase inhibitors. Recent drug patents targeting the Ras-MAPK pathway in cancer are becoming more selective with the potential for improved therapeutic response and better toxicity as compared to the more universal MAPK pathway inhibitors. In the present review we summarize the importance of the Ras-MAPK pathway in cancer with a focus on bladder cancer and discuss current drugs and recent patents (2004-2008) that target this important pathway in bladder cancer.
Export Options
About this article
Cite this article as:
Dangle P. Pankaj, Zaharieva Boriana, Jia Hongtao and Pohar S. Kamal, Ras-MAPK Pathway as a Therapeutic Target in Cancer - Emphasis on Bladder Cancer, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (2) . https://dx.doi.org/10.2174/157489209788452812
DOI https://dx.doi.org/10.2174/157489209788452812 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exploring Patterns of Epigenetic Information with Data Mining Techniques
Current Pharmaceutical Design Cancer Stem Cells of Head and Neck Squamous Cell Carcinoma
Current Cancer Therapy Reviews Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Intravesical Drug Delivery into the Bladder to Treat Cancers
Current Drug Delivery Chemotherapy for Laryngeal Cancer - An Apoptotic Approach
Current Drug Targets Labelling and Tracking of Human Mesenchymal Stromal Cells in Preclinical Studies and Large Animal Models of Degenerative Diseases
Current Stem Cell Research & Therapy Lanthanum, Gallium and their Impact on Oxidative Stress
Current Medicinal Chemistry Compound Ranking Based on a New Mathematical Measure of Effectiveness Using Time Course Data from Cell-Based Assays
Combinatorial Chemistry & High Throughput Screening Modulation of Cell Death in Age-Related Diseases
Current Pharmaceutical Design [General Articles] Intracellular Thiol Concentration Modulating Inflammatory Response: Influence on the Regulation of Cell Functions Through Cysteine Prodrug Approach
Current Medicinal Chemistry Review of 5-HT4R Ligands: State of Art and Clinical Applications
Current Topics in Medicinal Chemistry Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization
Current Clinical Pharmacology Microarrays and Colon Cancer in the Road for Translational Medicine
Current Bioinformatics DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design The Potential for Targeting Oncogenic WNT/β -Catenin Signaling in Therapy
Current Drug Targets Dimethylaminoparthenolide, A Water Soluble Parthenolide, Suppresses Lung Tumorigenesis Through Down-Regulating the STAT3 Signaling Pathway
Current Cancer Drug Targets Supramolecular Chiro-Biomedical Assays and Enantioselective HPLC Analyses for Evaluation of Profens as Non-Steroidal Anti-Inflammatory Drugs, Potential Anticancer Agents and Common Xenobiotics
Current Drug Discovery Technologies Development of Cisplatin Nanoparticles as Dry Powder Inhalers for Lung Cancer
Current Nanoscience Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Current Signal Transduction Therapy Immunotoxins and Other Conjugates: Pre-clinical Studies
Mini-Reviews in Medicinal Chemistry